CJC-1295 With DAC vs Without DAC: What's the Difference?

The primary difference between CJC-1295 with DAC and CJC-1295 without DAC (also called Modified GRF 1-29, or Mod GRF 1-29) is how long each remains active in circulation. The DAC form carries a chemistry that binds to blood albumin and extends its half-life to roughly six to eight days, producing prolonged stimulation of the growth-hormone axis. The without-DAC form lacks this binding and clears within about half an hour, generating a short, pulse-like signal. Both are members of the same GHRH-analogue class, and both are supplied strictly as research chemicals.

For research use only — not for human or veterinary use. The information below is educational and summarises published biochemistry and preclinical literature. It is not guidance to administer, dose, or use any compound, and human data on these peptides remains limited.

What is the GHRH-analogue class?

Growth hormone-releasing hormone (GHRH) is a signalling peptide that prompts the pituitary's somatotroph cells to release growth hormone. The full endogenous molecule is 44 amino acids long, but researchers in the 1980s observed that the first 29 residues — known as GRF (1-29) — retained most of the biological activity of the parent hormone. That truncated fragment became the scaffold for a family of synthetic analogues.

Native GRF (1-29) is fragile: enzymes in plasma degrade it within minutes. To address this, the analogue known as CJC-1295 introduced substitutions at several positions along the peptide backbone. These changes are intended to resist enzymatic breakdown and oxidation, improving stability during synthesis, storage, and in-solution studies compared with the unmodified fragment. This stabilised backbone is the shared foundation of both the with-DAC and without-DAC variants.

Why are there two versions?

The two forms diverge on a single design decision: whether or not an albumin-binding element is attached. That one addition is what separates a short-acting, pulsatile research tool from a long-acting one. Everything downstream — half-life, the pattern of growth-hormone signalling observed in models, and how the compound is typically studied — follows from it.

How does the DAC mechanism work?

DAC stands for Drug Affinity Complex. In the CJC-1295 with DAC molecule, a maleimidopropionic acid group is attached to the peptide via a lysine linker. Once the peptide enters circulation, this reactive group forms a stable covalent bond with cysteine-34 on serum albumin — the most abundant protein in blood plasma — through a chemical reaction known as Michael addition.

By tethering itself to albumin, the peptide effectively hides from the enzymes and kidney filtration that would otherwise clear a small peptide quickly. Albumin acts as a circulating carrier, releasing the bound peptide gradually. The reported outcome in preclinical work is a dramatic extension of half-life, from minutes to several days. You can review the specific research listing on the CJC-1295 with DAC product page.

What is the difference in CJC-1295 half life?

Half-life is the single most consequential difference between the two variants, and it shapes how each is used in a laboratory setting:

• CJC-1295 with DAC: A reported half-life of approximately six to eight days in preclinical studies, driven by albumin binding. This produces a sustained elevation of the growth hormone and IGF-1 axis — a broad, continuous "bleed" of signal rather than discrete peaks.
• CJC-1295 without DAC (Mod GRF 1-29): A plasma half-life of roughly 30 minutes. Because it clears rapidly, it generates a sharp, transient rise in growth-hormone signalling that more closely resembles the body's own pulsatile release pattern.

Neither profile is inherently "better" — they answer different research questions. The DAC form is often selected in models that call for prolonged, steady exposure, while the without-DAC form is chosen when investigators want to preserve the natural rhythm of growth-hormone secretion. The CJC-1295 without DAC listing covers the Mod GRF 1-29 form specifically.

What does pulsatile versus sustained signalling mean?

The body does not release growth hormone as a constant stream; it releases it in bursts, or pulses, with quiet intervals in between. The short half-life of Mod GRF 1-29 mirrors this — a quick on, quick off signal. The DAC form, by contrast, flattens that rhythm into continuous stimulation. This distinction is central to why researchers reach for one form over the other, and it is the main reason the two compounds are studied in different experimental designs.

Why is the without-DAC form paired with Ipamorelin in research?

In the published research literature, CJC-1295 without DAC is frequently investigated alongside a ghrelin receptor agonist such as Ipamorelin. The rationale is mechanistic. The two compounds act on separate receptors that both influence growth-hormone release:

• CJC-1295 (a GHRH analogue) signals through the GHRH receptor on somatotroph cells.
• Ipamorelin (a growth hormone secretagogue) signals through the GHSR-1a, or ghrelin, receptor.

Because these are two distinct pathways converging on the same outcome, models combining them have reported a synergistic amplification of growth-hormone pulses — a larger combined response than either compound produces alone. The short-acting Mod GRF 1-29 is the preferred GHRH partner here precisely because its pulsatile profile aligns with Ipamorelin's own timing, whereas the sustained DAC form would blunt the discrete-pulse dynamic being studied. Researchers exploring these combinations can browse related compounds in the TXLABS shop.

How do stability and handling compare?

In lyophilised (freeze-dried) powder form, both variants are relatively stable and, according to supplier data, can retain high purity for extended periods when stored cold — typically at or below -20°C for long-term storage, or 2–8°C short-term while the vial remains sealed and shielded from light and moisture. General handling considerations reported in laboratory protocols include:

• Allowing a vial to reach room temperature before opening, so condensation does not draw moisture into the powder.
• Reconstituting with a sterile solvent such as bacteriostatic water, directing the stream against the vial wall rather than onto the peptide cake to avoid foaming.
• Swirling gently to dissolve rather than shaking or vortexing, since mechanical stress can degrade peptide structure.
• Avoiding repeated freeze-thaw cycles and storing reconstituted solution refrigerated and protected from light.

Once in solution, stability is more limited than the dry powder, so most protocols treat reconstituted material as having a defined working window. Handling principles are broadly similar across both the DAC and no-DAC forms.

Which form suits a given research question?

The choice follows the experimental objective rather than any notion of potency. Studies requiring prolonged, continuous exposure to elevated growth-hormone signalling tend to favour the long-acting DAC variant. Studies concerned with preserving natural pulse architecture — or with pairing a GHRH analogue against a ghrelin agonist like Ipamorelin — tend to favour the short-acting Mod GRF 1-29. Human evidence for either compound remains limited, and the bulk of available data comes from preclinical and in-vitro settings.

For research use only — not for human or veterinary use. All compounds referenced are research-grade materials intended solely for laboratory investigation by qualified researchers.